In the claims:

1. (Currently Amended) A method of treating anxiety comprising the step of ~~applying~~ introducing into the central nervous system a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV (DP IV) enzyme whereby enzymatic activity of said enzyme is reduced.

2. (Currently Amended) A method for reducing degradation of the endogenous CNS-localized neuropeptide Y (NPY) for the treatment of, comprising the step of ~~applying~~ introducing into the central nervous system a therapeutically effective amount of a competitive inhibitor of the dipeptidyl peptidase (DP IV).

3. (Previously Presented) The method of claim 1 wherein said inhibitor is selected from the group consisting of N-(N`-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine.

4. (Previously Presented) The method of claim 1 wherein said inhibitor is present in a physiologically compatible drug delivery vehicle.

5. (Previously Presented) The method of claim 1 wherein said inhibitor is formulated in combination with NPY.

6. (Currently Amended) The method of claim 1 wherein introducing of said inhibitor of dipeptidyl peptidase IV is ~~applied~~ parenteral~~ly, enteraly, orally, by inhalation or suppository~~.

7. (Previously Presented) The method of claim 2 wherein said inhibitor is present in a physiologically compatible drug delivery vehicle.

8. (Cancelled)

9. (Previously Presented) The method of claim 3 wherein said inhibitor is formulated as prodrug of the free inhibitors.

10. (Currently Amended) The method of claim 2 wherein said introducing of said DP IV-inhibitor is ~~applied~~ parenteral~~ly, enteraly, orally, by inhalation or suppository~~.

11. (Currently Amended) The method of claim 3 wherein said introducing of said DP IV-inhibitor is ~~applied~~ parenteral~~ly, enteraly, orally, by inhalation or suppository~~.

12. (Currently Amended) The method of claim 4 wherein said introducing of said DP IV-inhibitor is ~~applied~~ parenteral~~ly, enteraly, orally, by inhalation or suppository~~.

13. (Currently Amended) The method of claim 5 wherein said introducing of said DP IV-inhibitor in combination with NPY is applied parenteral~~ly, enteraly, orally, by inhalation or suppository~~.

14. (Previously Presented) The method of claim 2, wherein said DP IV-inhibitor is selected from the group consisting of N-(N`-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine.

15. (Previously Presented) The method of claim 5, wherein said DP IV-inhibitor is selected from the group consisting of N-(N`-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine.